A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 5,900 shares of FHTX stock, worth $47,613. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,900
Previous 7,600 22.37%
Holding current value
$47,613
Previous $50,000 34.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.05 - $8.0 $206,428 - $327,016
40,877 Added 170.51%
64,850 $372,000
Q1 2024

May 15, 2024

BUY
$2.82 - $7.94 $67,603 - $190,345
23,973 New
23,973 $160,000
Q1 2023

May 15, 2023

BUY
$4.66 - $8.99 $416,096 - $802,726
89,291 Added 140.0%
153,072 $949,000
Q4 2022

Feb 14, 2023

SELL
$5.44 - $9.46 $21,275 - $36,998
-3,911 Reduced 5.78%
63,781 $406,000
Q3 2022

Nov 14, 2022

BUY
$7.52 - $18.01 $509,043 - $1.22 Million
67,692 New
67,692 $581,000

Others Institutions Holding FHTX

About Foghorn Therapeutics Inc.


  • Ticker FHTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,637,400
  • Market Cap $336M
  • Description
  • Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...
More about FHTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.